首页> 美国卫生研究院文献>other >Nanoscale Metal–Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy
【2h】

Nanoscale Metal–Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy

机译:纳米级金属有机框架克服了低氧对光动力疗法引发的癌症免疫疗法的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunotherapy has become a promising cancer therapy, but only works for a subset of cancer patients. Immunogenic photodynamic therapy (PDT) can prime cancer immunotherapy to increase the response rates, but its efficacy is severely limited by tumor hypoxia. Here we report a nanoscale metal–organic framework, Fe-TBP, as a novel nanophotosensitizer to overcome tumor hypoxia and sensitize effective PDT, priming non-inflamed tumors for cancer immunotherapy. Fe-TBP was built from iron-oxo clusters and porphyrin ligands and sensitized PDT under both normoxic and hypoxic conditions. Fe-TBP mediated PDT significantly improved the efficacy of anti-programmed death-ligand 1 (α-PD-L1) treatment and elicited abscopal effects in a mouse model of colorectal cancer, resulting in >90% regression of tumors. Mechanistic studies revealed that Fe-TBP mediated PDT induced significant tumor infiltration of cytotoxic T cells.
机译:免疫疗法已成为一种有前途的癌症疗法,但仅对部分癌症患者有效。免疫原性光动力疗法(PDT)可以引发癌症免疫疗法以提高缓解率,但其有效性受到肿瘤缺氧的严重限制。在这里,我们报告了一种纳米级的金属-有机骨架Fe-TBP,它是一种新型的纳米光敏剂,可以克服肿瘤的缺氧并敏化有效的PDT,从而引发用于癌症免疫治疗的非炎症性肿瘤。 Fe-TBP由铁-氧簇和卟啉配体构建,并在常氧和低氧条件下敏化了PDT。 Fe-TBP介导的PDT显着提高了抗编程死亡配体1(α-PD-L1)的治疗效果,并在结直肠癌的小鼠模型中引起了先后效应,导致肿瘤消退率> 90%。机理研究表明,Fe-TBP介导的PDT诱导明显的肿瘤浸润性细胞毒性T细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号